MediMabs

MediMabs is a company that specializes in the development and production of custom antibodies for research purposes. They offer a range of services, including monoclonal and polyclonal antibody development, antigen design and synthesis, and immunization protocols. The company uses a high-throughput automated platform to develop custom monoclonal antibodies, which allows for efficient clone testing and production of diverse clones. They also offer polyclonal antibody development services, including custom peptide synthesis, protein production, and affinity purification. Additionally, MediMabs provides vaccine development services, including antigen design, adjuvant pairing, and immunization regimen development. The company's products and services are designed to support researchers in various fields, including neuroscience, immunology, and microbiology, and are distributed worldwide.

Welcome to MédiMabs. Based in Montreal, Canada, we are a world-wide R&D multi-service and distribution company. Our mission is to be the most flexible and versitile R&D and service company to respond to the needs of researchers in the field of antibody application.

The MédiMabs moto, "From Researchers, for Researchers, by Researchers" is based on the company's dedication to provide optimal satisfaction at the level of end user application. To this end, MédiMabs introduces a new element to the commercialization of research grade antibodies. Through a supplemental royalty payment it secures the commitment of the provider to contribute to the technical support, thus bringing to the customer an extra level of confidence in the quality of Mabs and opportunities MédiMabs offers.

With the trend in medical research shifting from DNA sequencing towards protein based technology, MédiMabs brings to the scientist the antibodies they require to detect and monitor proteins. Furthermore, it facilitates the elucidation of the expression and function of the multitude of novel proteins arising from the success of the human genome sequencing.

Although MédiMabs intends to respond to the needs in most medical research areas, its primary focus includes licensing in the fields of neuroscience, neurofilaments, cancer, kinases, cytoskeleton and inflammation.